immunorock.com
Immunorock develops an oral immunotherapy platform utilizing bifidobacterium to create vaccines for cancer treatment and coronavirus prevention. This approach aims to provide patients with a more accessible and less invasive treatment option, enhancing their quality of life.
- Biotechnology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Current cancer treatments often involve invasive procedures and can significantly impact a patient's quality of life. Traditional vaccine delivery methods may also present challenges in terms of accessibility and patient compliance.
Solution
Immunorock is developing an oral immunotherapy platform that leverages bifidobacterium to deliver vaccines for cancer treatment. This approach aims to provide a more accessible and less invasive treatment option for patients. By utilizing an oral delivery method, Immunorock seeks to improve patient compliance and enhance their overall quality of life during cancer treatment. The platform is designed to be easily administered, potentially reducing the need for frequent clinic visits and improving convenience for patients.
Target Audience
The primary target audience includes cancer patients seeking less invasive treatment options and healthcare providers looking for innovative vaccine delivery methods.
Features
- Oral vaccine delivery system using bifidobacterium as a vector
- Targeted immunotherapy for cancer treatment
- Non-invasive administration method